Portales P - Search Results

1

T-Cell surface CCR5 density is not correlated with hepatitis severity in hepatitis C virus/HIV-coinfected individuals: implications for the therapeutic use of CCR5 antagonists.

Vincent T, Portales P, Baillat V, de Boever CM, Le Moing V, Vidal M, Ducos J, Clot J, Reynes J, Corbeau P. Vincent T, et al. Among authors: portales p. J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):305-9. J Acquir Immune Defic Syndr. 2005. PMID: 15735449

2

Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection.

Lin YL, Mettling C, Portales P, Reynes J, Clot J, Corbeau P. Lin YL, et al. Among authors: portales p. Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15590-5. doi: 10.1073/pnas.242134499. Epub 2002 Nov 14. Proc Natl Acad Sci U S A. 2002. PMID: 12434015 Free PMC article.

3

Low CD4+ T-cell surface CCR5 density as a cause of resistance to in vivo HIV-1 infection.

Reynes J, Baillat V, Portales P, Clot J, Corbeau P. Reynes J, et al. Among authors: portales p. J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):114-6. doi: 10.1097/00126334-200309010-00018. J Acquir Immune Defic Syndr. 2003. PMID: 14501804 No abstract available.

4

Diminished CD4+ T cell surface CCR5 expression in alcoholic patients.

Perney P, Portalès P, Clot J, Blanc F, Corbeau P. Perney P, et al. Among authors: portales p. Alcohol Alcohol. 2004 Nov-Dec;39(6):484-5. doi: 10.1093/alcalc/agh096. Epub 2004 Oct 21. Alcohol Alcohol. 2004. PMID: 15498817

5

CXCR4 overexpression during the course of HIV-1 infection correlates with the emergence of X4 strains.

Lin YL, Portales P, Segondy M, Baillat V, de Boever CM, Le Moing V, Réant B, Montes B, Clot J, Reynes J, Corbeau P. Lin YL, et al. Among authors: portales p. J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):530-6. J Acquir Immune Defic Syndr. 2005. PMID: 16044003

6

The efficiency of R5 HIV-1 infection is determined by CD4 T-cell surface CCR5 density through G alpha i-protein signalling.

Lin YL, Mettling C, Portalès P, Réant B, Robert-Hebmann V, Reynes J, Clot J, Corbeau P. Lin YL, et al. Among authors: portales p. AIDS. 2006 Jun 26;20(10):1369-77. doi: 10.1097/01.aids.0000233570.51899.e2. AIDS. 2006. PMID: 16791011

7

The immunological response to highly active antiretroviral therapy is linked to CD4+ T-cell surface CCR5 density.

Vincent T, Portalès P, Baillat V, Eden A, Clot J, Reynes J, Corbeau P. Vincent T, et al. Among authors: portales p. J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):377-8. doi: 10.1097/01.qai.0000234088.64655.45. J Acquir Immune Defic Syndr. 2006. PMID: 17079996 No abstract available.

8

The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density.

Desmetz C, Lin YL, Mettling C, Portalès P, Rabesandratana H, Clot J, Corbeau P. Desmetz C, et al. Among authors: portales p. Immunology. 2006 Dec;119(4):551-61. doi: 10.1111/j.1365-2567.2006.02470.x. Immunology. 2006. PMID: 17177831 Free PMC article.

9

The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5.

Lin YL, Mettling C, Portalès P, Rouzier R, Clot J, Reynes J, Corbeau P. Lin YL, et al. Among authors: portales p. AIDS. 2008 Jan 30;22(3):430-2. doi: 10.1097/QAD.0b013e3282f46a6f. AIDS. 2008. PMID: 18195571

10

Pairwise comparison of isogenic HIV-1 viruses: R5 phenotype replicates more efficiently than X4 phenotype in primary CD4+ T cells expressing physiological levels of CXCR4.

Fiser AL, Lin YL, Portalès P, Mettling C, Clot J, Corbeau P. Fiser AL, et al. Among authors: portales p. J Acquir Immune Defic Syndr. 2010 Feb;53(2):162-6. doi: 10.1097/QAI.0b013e3181c72033. J Acquir Immune Defic Syndr. 2010. PMID: 20051874

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

72 results

Search Page

Filters